Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...
Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback